The China MedTech Edge: November 2025 Intelligence Briefing

Delivering essential intelligence on China’s MedTech ecosystem: Policy & Compliance, Innovation, Global Strategy and beyond.

December 5, 2025

The Chinese medical device industry moved steadily forward in November 2025, propelled by clear policy guidance and active market innovation. The regulatory framework continued to be refined, strengthening the foundation for product safety and industry advancement. The approval of several innovative products underscored the industry’s R&D capabilities, and clinical research achieved globally recognized breakthroughs in neuroscience and intelligent surgery. Furthermore, domestic enterprises accelerated their international growth, successfully exporting high-end products, while the capital market showed sustained interest in both early-stage frontier technologies and the consolidation of established platforms.

I. Medical Device Policies and Regulations

The policy environment continued to improve, featuring a multi-layered structure of national standardization and targeted local support. Regulatory policies strictly upheld product quality and safety while vigorously encouraging innovation and industrial upgrading. Institutional reforms also enhanced the efficiency of the review and approval processes, providing clear momentum for high-quality industry development.

Key Regulatory Updates in November 2025:

  • November 3: Guidance Principle for Registration Review of Intracranial Thrombectomy Stents (NMPA CDE). This guidance standardizes the registration application and technical review for Class III cerebral thrombus removal devices, detailing required documentation from regulatory information to quality management files.
  • November 4: Revised Good Manufacturing Practice for Medical Devices (GMP) (NMPA). The new GMP systematically integrates recent global concepts of quality risk management and quality system requirements. Key features include: full-process quality risk management, strengthened quality assurance for stable mass production, clarified responsibilities in new models (like commissioned manufacturing), emphasis on Verification and Confirmation, and encouragement of digital transformation, including AI, IT, and Unique Device Identification (UDI).
  • November 24: Several Measures to Promote the High-Quality Development of Beijing’s Medical Device Industry (6 departments, Beijing). Beijing issued 15 strong support measures covering clinical R&D, market registration, local production, promotion, cluster development, digital empowerment, and overseas expansion. The goal is to build an internationally influential hub for high-end innovative medical devices.
  • November 24: Measures for Deepening Reform of Drug and Medical Device Regulation (Shanghai). This document includes 22 specific measures. For Class II devices with significant clinical value and strong innovation, Shanghai encourages the use of the special innovative review procedure. By optimizing guidance and service mechanisms, the city aims to compress the average cycle for first-time Class II registration to within 6 months.

II. Latest Approved Innovative Medical Devices

In November 2025, four innovative medical device products were approved for market launch via Green Channel, focusing on key areas such as AI-enabled diagnostics, minimally invasive interventional treatment, precise cardiac ablation, and complex surgical solutions:

  1. Prostate Cancer MR Image Assisted Detection Software (Shanghai Siemens Healthcare Medical Instruments Co., Ltd.): An AI medical device using deep learning technology to assist in detecting suspected prostate adenocarcinoma lesions in adults aged 40+ during MR image analysis. It aims to improve reading quality and reduce unnecessary biopsies.
  2. Thoraco-Abdominal Aortic Covered Stent System (LifeTech Scientific (Shenzhen) Co., Ltd.): A multi-component system used for the endovascular repair of thoraco-abdominal aortic aneurysms.
  3. Disposable Pressure Monitoring Cardiac Pulsed Field Ablation Catheter (MicroPort EP MedTech (Shanghai) Co., Ltd.): Uses a strain gauge-based pressure sensor, Pulsed Field Ablation (PFA), magnetic localization, and saline irrigation technology. It is used with PFA equipment to treat Atrioventricular Nodal Reentrant Tachycardia (AVNRT) and Atrioventricular Reentrant Tachycardia (AVRT), offering more options for Supraventricular Tachycardia (SVT) treatment.
  4. Branched Intraoperative Aortic Stent System (PerMedos Co., Ltd.): A branched stent and delivery system used for the surgical open repair of Stanford Type A Aortic Dissection. A detailed product introduction is featured in the Recent Launched Products.

III. Clinical Innovation Breakthrough

“Active Knot Smart Sutures” Research (Zhejiang University)

On November 27, a research team from Zhejiang University achieved international recognition, with their findings published on the cover of Nature. The team successfully elucidated the “mechanical transmission mechanism based on active knots” and proposed an innovative “active knot smart suture.” This technology was successfully applied to surgical suturing and is expected to guide the design of future robots and smart structures.

IV. Internationalization and Overseas Expansion

Chinese medtech companies demonstrated solid international growth this month, marked by breakthroughs of high-end products and the successful debut of emerging technologies, supported by a growing systematic ecosystem:

  • Shanxi Jinbo Biotechnology Co., Ltd. (Nov 24): Its Recombinant Type III Humanized Collagen Lyophilized Fiber obtained a Class D Medical Device Registration Certificate in the Philippines. The high-end implantable device is indicated for filling facial dermal tissue to correct dynamic wrinkles on the forehead.
  • Sinomed (Nov 26): Its independently developed HT Supreme™ Drug-Eluting Stent System was approved for registration by the Drug Regulatory Authority of Pakistan (DRAP). This product is noted as the first cardiac stent from a Chinese manufacturer to undergo simultaneous pre-market clinical studies and registration applications in China, the US, Japan, and Europe.

V. Investment, Financing, and M&A Events

Capital activity spanned the entire chain, from early-stage incubation to mature business consolidation. Investment continues to be channeled into core tracks such as cardiovascular intervention, while also expanding into innovative fields like frontier imaging:

  • Hefei Jiayu Technology (Financing, Nov 12): Completed an Angel round of over 10 million RMB for the registration application and clinical promotion of its core product, the Handheld Magnetic Particle Imaging (MPI) System, accelerating the industrialization of MPI technology.
  • MicroPort CardioFlow (M&A, Nov 25): Announced the full acquisition of MicroPort CRM (Cardio Rhythm Management) for $680 million (approx. 4.8 billion RMB).
  • TRULIVE Medical Technology Co., Ltd. (Financing, Nov 28): Completed over 100 million RMB in Series C financing. The company is a platform-based interventional innovation enterprise focusing on “blood flow management” across high-end medical devices for cardiovascular, peripheral vascular, and structural heart disease.